Clinical Trials Browser

Bile Duct Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT06751394 2024-12-27

TRACER

Phase 2 Not yet recruiting

44 enrolled

Gastrointestinal

Rectal Neoplasms

NCT05000697 2024-11-27

CCHOWW

Phase NA Recruiting

216 enrolled

Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT05424692 2024-11-04

Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer

Phase NA Recruiting

200 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT06665087 2024-10-30

CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC

Phase 2 Not yet recruiting

110 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT06652412 2024-10-28

CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC

Phase 2 Not yet recruiting

124 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT00807911 2024-10-23

Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer

Phase 2 Completed

322 enrolled 20 charts

Gastrointestinal

Rectal Neoplasms

NCT04679597 2024-10-17

Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for Failure

Completed

161 enrolled

Gastrointestinal

Rectal Neoplasms

NCT05628038 2024-10-01

TORCH-R

Phase 2 Recruiting

93 enrolled

Gastrointestinal

Rectal Neoplasms

NCT04246684 2024-09-19

Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients

Phase 3 Active not recruiting

702 enrolled

Gastrointestinal

Rectal Neoplasms

NCT06504875 2024-07-17

Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer

Not yet recruiting

23 enrolled

Gastrointestinal

Rectal Neoplasms

NCT06390982 2024-04-30

Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study

Phase 2 Not yet recruiting

46 enrolled

Gastrointestinal

Rectal Neoplasms

NCT06266832 2024-02-20

The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma

Phase 2 Recruiting

30 enrolled

Gastrointestinal

Rectal Neoplasms

NCT03698461 2024-01-31

CLIMB

Phase 2 Completed

20 enrolled

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT03729687 2023-11-30

LARCT-US

Phase 2 Unknown

280 enrolled

Gastrointestinal

Rectal Neoplasms

NCT02017704 2023-10-17

CORRECT

Phase 2 Completed

9 enrolled 9 charts

Gastrointestinal

Rectal Neoplasms

NCT05081687 2023-10-11

BRAZIL-TNT

Phase 3 Unknown

150 enrolled

Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms

NCT05307198 2023-10-10

RAIC

Phase 2 Unknown

38 enrolled

Gastrointestinal

Rectal Neoplasms

Clinical Trials

SCOTI

SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

FOBEAR

Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression

A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in High-Risk Locally Advanced Rectal Cancer

Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

GRECCAR8

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

SHORT

Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer

A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

COCHISE

SPARC

Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

mRCAT-III

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer

Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer

Short-course Radiotherapy or Long-course Chemoradiation Followed by MFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer

SCRIPBOT

Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer

CASINOs

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

TRACER

CCHOWW

Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer

CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC

CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC

Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer

Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for Failure

TORCH-R

Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients

Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer

Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study

The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma

CLIMB

LARCT-US

CORRECT

BRAZIL-TNT

RAIC